Evidence map›Paper›PMID 40634667›Full record

ArticleNPJ precision oncology2025

Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer.

Karl Semaan, Rashad Nawfal, John Canniff, Hunter Savignano, Ji-Heui Seo, Stephanie E Siegmund, Sarah J Wu, Julia K Rotow, Gwo-Shu Mary Lee, Razane El Hajj Chehade and 12 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Karl Semaan *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rashad Nawfal *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John CanniffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hunter SavignanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Stephanie E SiegmundDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Sarah J WuDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Julia K RotowLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gwo-Shu Mary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Razane El Hajj ChehadeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ze ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gunsagar S GulatiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Noa PhillipsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Garyoung Gary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Christopher A FrenchDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Michelle S HirschDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Heather A JaceneDepartment of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA.
Atish D ChoudhuryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. sylvan_baca@dfci.harvard.edu.
Jacob E BerchuckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. jberchuck@emory.edu.

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discoveryU01CA296432 · NCI · DANA-FARBER CANCER INST · PI Sylvan C. Baca · 2025 to 2026
$1.4M
NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA296432
6 · The paper itself

Abstract

Squamous transformation of prostate adenocarcinoma is a rare resistance mechanism in patients with advanced prostate cancer that impacts both prognosis and treatment. Herein, we profile circulating chromatin in serial plasma samples collected from a patient with metastatic prostate cancer that experienced squamous transformation. We detect dynamic changes in gene regulation from circulating chromatin reflecting the emergence of squamous differentiation, enabling non-invasive diagnosis and monitoring of this resistance phenotype, with potential therapeutic implications.

Identifiers

PMID40634667
PMCPMC12241565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.